Johnson & Johnson is poised to settle a historic $5.5 billion talc lawsuit over ovarian cancer claims, pending approval from at least 95% of plaintiffs — a move that comes after a previous $9 billion deal was rejected by a judge. With legal hurdles now requiring plaintiffs to prove direct causation — a burden they can’t meet — the company sees this settlement as a strategic exit, freeing them to focus on life-saving innovations. The initial $3 billion payment won’t hit until next year, with no more due until 2028. Investors responded positively, sending shares up over 2% — betting on a clean break from a decade-long legal storm.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
